BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/14/2018 11:38:00 AM | Browse: 1233 | Download: 2318
 |
Received |
|
2018-03-30 09:07 |
|
Peer-Review Started |
|
2018-03-30 09:21 |
|
First Decision by Editorial Office Director |
|
2018-04-27 17:25 |
|
Return for Revision |
|
2018-05-03 06:36 |
|
Revised |
|
2018-06-11 09:08 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2018-06-27 08:10 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2018-06-28 15:29 |
|
Articles in Press |
|
2018-06-28 15:29 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-09-11 07:21 |
|
Publish the Manuscript Online |
|
2018-09-14 11:38 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Candice Carola, Francois Ghiringhelli, Stefano Kim, Thierry Andre, Juliette Barlet, Leila Bengrine-Lefevre, Helene Marijon, Marie-Line Garcia-Larnicol, Christophe Borg, Linda Dainese, Nils Steuer, Hubert Richa, Magdalena Benetkiewicz, Annette K Larsen, Aimery de Gramont and Benoist Chibaudel |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Benoist Chibaudel, MD, Department of Medical Oncology, Franco-British Institute, 4 rue Kléber, Levallois-Perret 92300, France. benoist.chibaudel@ihfb.org |
| Key Words |
Chemotherapy; Irinotecan; Aflibercept; Second-line; Colorectal cancer |
| Core Tip |
Results obtained in this retrospective study show that minimally modified FOLFIRI has improvement dramatically the efficacy of the FOLFIRI3-aflibercept combination with high response rates and survivals in patients with previously treated metastatic colorectal cancer, whatever prior use of irinotecan. A prospective randomized trial is planned to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept. |
| Publish Date |
2018-09-14 11:38 |
| Citation |
Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, de Gramont A, Chibaudel B. FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. World J Clin Oncol 2018; 9(5): 110-118 |
| URL |
http://www.wjgnet.com/2218-4333/full/v9/i5/110.htm |
| DOI |
http://dx.doi.org/10.5306/wjco.v9.i5.110 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
